Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Immunomedics, Inc.    IMMU

Delayed Quote. Delayed  - 07/22 10:00:00 pm
2.68 USD   +3.47%
07/23 IMMUNOMEDICS SH : Kahn Swick & Foti, LLC Reminds Investors with Loss..
07/15 SHAREHOLDER NOT : Goldberg Law PC Announces Securities Class Action ..
07/15 Levi & Korsinsky, LLP Reminds Shareholders of Immunomedics, Inc. ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Immunomedics To Receive $16.7 Million Payment to Resolve Finra Proceedings

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/02/2013 | 12:11am CEST
   By Kristin Jones 
 

Immunomedics Inc. (>> Immunomedics, Inc.) expects to receive a total payment of $16.7 million after reaching a settlement with its former broker, resolving allegations the drug company had brought to the Financial Industry Regulatory Authority related its investments.

Immunomedics said Monday that it will receive a gross settlement amount of $18 million, excluding expenses and legal fees, and has agreed to dismiss the proceeding with prejudice against an unnamed broker.

The company has said in filings that in 2009, it initiated an arbitration proceeding before Finra against its former investment advisor, former Bank of America Corp. (>> Bank of America Corp) units Banc of America Investment Services Inc. and Banc of America Securities LLC. Immunomedics accused the firm of making false representations or omissions concerning auction rate securities.

A representative from Bank of America wasn't immediately available for comment.

Immunomedics focuses primarily on the development of treatments for cancer and other serious diseases.

Its shares closed Monday up 1.2% at $2.44 and were unchanged after hours. The stock is down 16% since the start of the year.

Write to Kristin Jones at kristin.jones@dowjones.com

Stocks mentioned in the article : Immunomedics, Inc., Bank of America Corp
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOMEDICS, INC.
07/23 IMMUNOMEDICS SHAREHOLDER ALERT BY FO : Kahn Swick & Foti, LLC Reminds Investors ..
07/21 IMMUNOMEDICS, INC. : IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securiti..
07/19 IMMUNOMEDICS, INC. : DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds ..
07/16 IMMUNOMEDICS, INC. : Pomerantz Law Firm Reminds Shareholders with Losses on thei..
07/15 SHAREHOLDER NOTICE : Goldberg Law PC Announces Securities Class Action Lawsuit a..
07/15 Levi & Korsinsky, LLP Reminds Shareholders of Immunomedics, Inc. of Commencem..
07/14 IMMUNOMEDICS, INC. : Khang & Khang LLP Announces the Filing of a Securities Clas..
07/14 IMMUNOMEDICS, INC. : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Noti..
07/11 Lundin Law PC Announces Securities Class Action Lawsuit against Immunomedics ..
07/11 IMMUNOMEDICS, INC. : Lundin Law PC Announces Securities Class Action Lawsuit aga..
More news
Sector news : Biotechnology & Medical Research - NEC
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/12DJAmgen Biosimilar Gets Thumbs-Up From FDA Panel
07/12DJJuno to Resume Clinical Trial of Anticancer Treatment
07/09DJCorrections & Amplifications -- WSJ
07/08DJAMGEN : Theranos Dealt Blow as Holmes Is Banned From -2-
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
07/07 EVOLUTION OF CANCER THERAPY : The Missing Linker
06/28 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
06/21 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
06/21 New finance chief at Immunomedics
06/10 After Hours Gainers / Losers
Advertisement
Financials ($)
Sales 2016 3,50 M
EBIT 2016 -55,6 M
Net income 2016 -55,7 M
Debt 2016 -
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
Capi. / Sales 2016 72,6x
Capi. / Sales 2017 20,0x
Capitalization 254 M
More Financials
Chart IMMUNOMEDICS, INC.
Duration : Period :
Immunomedics, Inc. Technical Analysis Chart | IMMU | US4529071080 | 4-Traders
Full-screen chart
Technical analysis trends IMMUNOMEDICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 5,00 $
Spread / Average Target 87%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Cynthia L. Sullivan President, Chief Executive Officer & Director
David M. Goldenberg Chairman, Chief Scientific & Patent Officer
Michael R. Garone Chief Financial Officer & Vice President-Finance
William A. Wegener Chief Medical Officer
Brian A. Markison Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOMEDICS, INC.-12.70%254
INCYTE CORPORATION-20.32%16 212
CELLTRION, INC.--.--%10 689
LONZA GROUP AG11.40%9 737
QUINTILES TRANSNATIONA..7.82%8 859
ALKERMES PLC-37.26%7 528
More Results